Hanall Biopharma Co., Ltd. (KRX:009420)

South Korea · Delayed Price · Currency is KRW

57,400

+1,200 (2.14%)

At close: Mar 18, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Manufacture and Sale of Pharmaceuticals		134.91B	110.00B	101.59B	88.60B	108.45B
Manufacture and Sale of Pharmaceuticals Growth		22.65%	8.27%	14.66%	-18.30%	18.09%
Total		134.91B	110.00B	101.59B	88.60B	108.45B
Total Growth		22.65%	8.27%	14.66%	-18.30%	18.09%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
South Korea		134.84B	109.96B	101.58B	88.46B	108.13B
South Korea Growth		22.63%	8.25%	14.83%	-18.19%	18.28%
Export		70.63M	35.74M	16.07M	143.75M	320.26M
Export Growth		97.61%	122.41%	-88.82%	-55.11%	-23.05%
Total		134.91B	110.00B	101.59B	88.60B	108.45B
Total Growth		22.65%	8.27%	14.66%	-18.30%	18.09%

Source: S&P Global Market Intelligence.